Mepilex XT in practice

hidden1hidden2

Effective exudate management has been shown to contribute to a reduction in time to wound healing, a reduction in skin damage and risk of infection, whilst improving patient quality of life and healthcare efficiency
It is important that clinicians find a balance between the beneficial and damaging effects of wound exudate; this will help to achieve moist wound healing, while minimising the risk of moisture-related damage to the wound and periwound skin
Focus should be on the nature of wound exudate as well as exudate volume; the clinical and economic challenges posed by different exudate types should be considered when developing an exudate management plan
Mepilex XT incorporates exudate channels, designed to draw both low and high viscosity exudate away from the wound bed, helping to protect the wound and peri-wound area from moisture-related damage

hidden1hidden2

Aims

To evaluate the performance of Mepilex XT in clinical practice, when used as part of the wound management regimen in a variety of wound types.

Registry study, conducted across 10 specialised wound care centres in Germany; all of the centres work with the same standard treatment path and use a digital wound documentation system
Mepilex XT was used across all 10 wound care centres over an 8-month period
A number of different wound types were included in the study, including arterial/mixed/venous ulcers, traumatic wounds, diabetic/neuropathic ulcers, decubitus ulcers and neoplastic wounds. These wounds were located in a variety of anatomical locations
For each wound treated with Mepilex XT, data captured at each scheduled dressing change (over a period of up to 6 weeks) were analysed; typically, patients are seen at the clinic every 2 weeks
A number of wound-related and dressing-related parameters were tracked (Table 1)

Table 1: Scope of data extraction from digital wound documentation system for inclusion in the analysis

Wound-related parameters
Types
International Classification of Diseases (ICD-10)
Age at start of treatment
Location
Size
Condition
Exudate
Signs of infection

Dressing-related parameters
Treatment duration
Wear time/interval between dressing changes
Ease of dressing changes
Pain at dressing changes

hidden1hidden2

Results

During the evaluation period, 136 patients (52.2% female; 47.8% male) had wounds appropriate for treatment with Mepilex XT; wounds with no exudate were not considered suitable for treatment with the dressing
By week 2, a reduction in wound size was observed from a mean of 11.8cm² (SD 20.62) at baseline to 6.6cm² (SD 10.96) at week 2; this reduction in wound size continued into week 4 and week 6 (Figure 1)
From baseline to week 6 of treatment, a healing rate of 31% was observed
Mepilex XT dressings were observed to effectively handle wound exudate, irrespective of the quantity, type and/or viscosity
No observation of leakage or maceration was reported throughout the study
Median total treatment duration with the dressing was 39 days (range 7-309 days); during this treatment duration, the median number of dressing changes per week was 3 (range 1-7)
At dressing changes, Mepilex XT dressings were found to be easy to remove in over 85% of dressing changes
An overall reduction in pain severity at dressing change from baseline to week 6 was observed (pain data based on 18 patients, as other patients did not experience pain at all at dressing change)

hidden1hidden2

Conclusions

During this study, those wounds treated with Mepilex XT generally demonstrated a good healing response in terms of a reduction in wound size
The dressing effectively managed different types of wound exudate, including high viscosity exudate. As such, the dressing demonstrated its potential to be used throughout the various wound healing stages
The dressing also demonstrated relatively long wear times, indicating potentially positive implications on cost-effectiveness

hidden1hidden2

hidden2

Products and solutions

hidden2

Mepilex XT

Highly absorbent foam dressing for normal and viscous exudate